1. First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. (5th January 2021) Authors: Kaul, M.; Jarvis, P.; Rozenberg, I.; Kolbinger, F.; Di Padova, F.; Calonder, C.; Espie, P.; Rondeau, J.M.; Cebe, R.; Huber, T.; Mussmann, R.; Aassi, M.; Sligh, T.S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 5(2021) Page Start: 1143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗